The tyrosine kinase inhibitor (TKI) imatinib produces mast cell deficiency in Ph plus chronic myeloid leukemia

被引：0
|
作者：
Cerny-Reiterer, S. [1 ,2 ]
Herndlhofer, S. [2 ]
Stefanzl, G. [2 ]
Blatt, K. [2 ]
Hoermann, G. [3 ]
Muellauer, L. [4 ]
Beham-Schmid, C. [5 ]
Baumgartner, S. [6 ]
Sperr, W. S. R. [2 ]
Mannhalter, C. [3 ]
Linkesch, W. [7 ]
Valent, P. [1 ,2 ]
机构：
[1] Ludwig Boltzmann Cluster Oncol, Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
[3] Med Univ Vienna, Dept Lab Med, Vienna, Austria
[4] Med Univ Vienna, Dept Pathol, Vienna, Austria
[5] Med Univ Graz, Inst Pathol, Graz, Austria
[6] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria
[7] Med Univ Graz, Dept Internal Med, Div Haematol, Graz, Austria
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [1] THE BCR/ABL TYROSINE KINASE INHIBITOR IMATINIB PRODUCES PROFOUND MAST CELL DEFICIENCY IN CHRONIC MYELOID LEUKEMIA
    Cerny-Reiterer, S.
    Herndlhofer, S.
    Stefanzl, G.
    Blatt, K.
    Hoermann, G.
    Muellauer, L.
    Beham-Schmid, C.
    Baumgartner, S.
    Sperr, W.
    Mannhalter, C.
    Linkesch, W.
    Valent, P.
    HAEMATOLOGICA, 2013, 98 : 293 - 293
  • [2] Long-term treatment with imatinib results in profound mast cell deficiency in Ph plus chronic myeloid leukemia
    Cerny-Reiterer, Sabine
    Rabenhorst, Anja
    Stefanzl, Gabriele
    Herndlhofer, Susanne
    Hoermann, Gregor
    Muellauer, Leonhard
    Baumgartner, Sigrid
    Beham-Schmid, Christine
    Sperr, Wolfgang R.
    Mannhalter, Christine
    Sill, Heinz
    Linkesch, Werner
    Arock, Michel
    Hartmann, Karin
    Valent, Peter
    ONCOTARGET, 2015, 6 (05) : 3071 - 3084
  • [3] Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
    Haznedaroglu, Ibrahim C.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
  • [4] Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph plus ) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).
    Maiti, Abhishek
    Ravandi, Farhad
    Cortes, Jorge E.
    Jabbour, Elias
    Marx, Kayleigh
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Benton, Christopher Brent
    Masarova, Lucia
    Dinardo, Courtney Denton
    Bose, Prithviraj
    Naqvi, Kiran
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Short, Nicholas James
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
    Barber, Mary C.
    Mauro, Michael J.
    Moslehi, Javid
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 110 - 114
  • [6] A Role for Lipid Metabolism in Tyrosine Kinase Inhibitor (TKI) Resistance of Chronic Myeloid Leukemia (CML)
    Gonzalez, Mayra A.
    Lopez, Jose L.
    Schenkel, Katherine
    Reffell, Kelaiah
    A.Eide, Christopher
    Bajpeyi, Sudip
    M.Eiring, Anna
    BLOOD, 2021, 138
  • [7] Imatinib Mesilate -: Treatment of chronic myeloid leukemia Brc-Abl tyrosine kinase inhibitor
    de Bree, F
    Sorbera, LA
    Fernández, R
    Castañer, J
    DRUGS OF THE FUTURE, 2001, 26 (06) : 545 - 552
  • [8] Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia
    Demirkan, Fatih
    Sevindik, Omur Gokmen Gokmen
    Karaman, Aysegul
    Alacacioglu, Inci
    Solmaz, Serife Medeni
    Ozsan, Guner Hayri
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
    Ciftciler, R.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7787 - 7798
  • [10] Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).
    Chen, Yaozhu J.
    Huang, Hui
    Divino, Victoria
    Pokras, Shibani
    Hallinan, Shawn
    Munakata, Julie
    Taylor, Catherine
    McGarry, Lisa
    Ng, Daniel
    Nieset, Christopher
    Knopf, Kevin B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345